Reply to: "Cost-effectiveness of upcoming treatments for hepatitis C: we need to get the models right"

Affiliations

¹ Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; Betty & Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA. Electronic address: zobair.younossi@inova.org.
² Betty & Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.
³ Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA.

Free article

Comment

Zobair M Younossi et al. J Hepatol. 2014 Aug.

Free article

. 2014 Aug;61(2):454-5.

doi: 10.1016/j.jhep.2014.05.006. Epub 2014 May 10.

¹ Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; Betty & Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA. Electronic address: zobair.younossi@inova.org.
² Betty & Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA.
³ Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA.

No abstract available

Comment on

Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
Younossi ZM, Singer ME, Mir HM, Henry L, Hunt S. Younossi ZM, et al. J Hepatol. 2014 Mar;60(3):530-7. doi: 10.1016/j.jhep.2013.11.009. Epub 2013 Nov 19. J Hepatol. 2014. PMID: 24269472
Cost-effectiveness of upcoming treatments for hepatitis C: we need to get the models right.
Tsochatzis EA, Crossan C, Longworth L. Tsochatzis EA, et al. J Hepatol. 2014 Aug;61(2):453-4. doi: 10.1016/j.jhep.2014.04.022. Epub 2014 Apr 26. J Hepatol. 2014. PMID: 24780301 No abstract available.